Cannabinoids for drug-resistant seizures in a critically ill patient-Case report and literature review.
cannabidiol
cannabis
drug-resistant
epilepsy
neurology
seizures
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
12
08
2019
revised:
30
10
2019
accepted:
04
11
2019
pubmed:
27
11
2019
medline:
3
2
2021
entrez:
27
11
2019
Statut:
ppublish
Résumé
Drug-resistant seizures are life-threatening and contribute to sustained hospitalization. We present the case of a critically ill 28-year-old male with Lennox-Gastaut syndrome who had approximately 30 seizures/day in the intensive care unit. Patient required mechanical ventilation and pharmacologically induced thiopentone coma. He was commenced on cannabidiol and subsequently extubated. He remained seizure-free thereafter on a combination of cannabidiol and anti-epileptic medication that predated his critical illness. Our case report provides a unique perspective on the role of cannabidiol in achieving remission from drug-resistant seizures in critically ill patients.
Substances chimiques
Anticonvulsants
0
Cannabidiol
19GBJ60SN5
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
570-572Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319.
Golyala A, Kwan P. Drug development for refractory epilepsy: The past 25 years and beyond. Seizure. 2017;44:147-156.
Devinsky O. Patients with refractory seizures. N Engl J Med. 1999;340(20):1565-1570.
Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70(Pt B):313-318.
Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133-150.
Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ. 2019;365:l1141.
NabiximolsPublic Summary Document. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/nabiximols. Accessed June 07, 2019.
Suraev AS, Todd L, Bowen MT, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav. 2017;70(Pt B):334-340.
Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270-278.
Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018;378(20):1888-1897.
Hausman-Kedem M, Menascu S, Kramer U. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain Devt. 2018;40(7):544-551.
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096.
Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741-753.
Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59(8):1540-1548.
Szaflarski JP, Bebin EM, Cutter G, et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018;87:131-136.
Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ(9)-tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142-154.
Hegde M, Santos-Sanchez C, Hess CP, et al. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy Behav. 2012;25(4):563-566.
Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurolog Dis. 2007;4(2):103-106.
Sivakumar S, Zutshi D, Seraji-Bozorgzad N, Shah AK. Effects of marijuana on ictal and interictal EEG activities in idiopathic generalized epilepsy. J Clin Neurophysiol. 2017;34(1):e1-e4.
Ladino LD, Hernandez-Ronquillo L, Tellez-Zenteno JF. Medicinal marijuana for epilepsy: a case series study. Can J of Neurol Sci. 2014;41(6):753-758.
Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419-428.
Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results. Epilepsy Res. 2019;154:13-20.
Bruce D, Brady JP, Foster E, Shattell M. Preferences for medical marijuana over prescription medications among persons living with chronic conditions: alternative, complementary, and tapering uses. J Altern Complement Med (New York, NY). 2018;24(2):146-153.
Crowell TL. Therapeutic value of medical marijuana in New Jersey patients: a community partnership research endeavor. J Allied Health. 2017;46(4):232-238.
Massot-Tarrus A, McLachlan RS. Marijuana use in adults admitted to a Canadian epilepsy monitoring unit. Epilepsy Behav. 2016;63:73-78.
McConnell BV, Applegate M, Keniston A, et al. Use of complementary and alternative medicine in an urban county hospital epilepsy clinic. Epilepsy Behav. 2014;34:73-76.
Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78(17):1791-1804.